A Phase 3 interventional study of TP-03 and TP-03 Vehicle in Blepharitis, sponsored by Tarsus Pharmaceuticals, Inc.. Completed at 21 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-21.
Sponsored by Tarsus Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment
The purpose of this study is to compare the safety and efficacy of TP-03, an eyedrop, to its vehicle control for the treatment of blepharitis due to Demodex, a microscopic mite frequently found in human hair follicles.
This Phase 3 study is a randomized, controlled, multicenter, double-masked, parallel trial to compare the safety and efficacy of TP-03 to vehicle control for the treatment of Demodex blepharitis. The primary objective of the study is to assess the safety and efficacy of TP-03, 0.25% compared to its vehicle from Day 1 to Day 43 in adult participants with mild to severe Demodex blepharitis. The primary efficacy endpoint will be cure based upon collarettes. Safety will be determined by assessing adverse effects related to the treatment as well as evaluating any changes in visual acuity, intraocular pressure, slit lamp biomicroscopy, endothelial cell density, hematology, blood chemistry, and urinalysis.
73 studies on the registry are indexed under Blepharitis; 9 are open to participants now.
This study's enrollment of 412 is above the median of 60 across 65 interventional studies indexed under Blepharitis.
Browse Blepharitis studies →Tarsus Pharmaceuticals, Inc. is the lead sponsor of 13 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 3 (38%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TP-03, lotilaner ophthalmic solution, 0.25%, administered topically twice a day for approximately 43 days
Drug: TP-03
Vehicle of TP-03 ophthalmic solution, administered topically twice a day for approximately 43 days
Drug: TP-03 Vehicle
TP-03, lotilaner ophthalmic solution, 0.25%, administered twice a day
Vehicle of TP-03 ophthalmic solution, administered twice a day
The Proportion of Participants Cured Based on Their Collarette Score of 0 for the Upper Eyelid.
The proportion of subjects cured where cure is defined as 0-2 lashes with collarettes on the upper eyelid of the analysis eye. The primary outcome analysis is the combined result from 20 analyses each with missing data imputed. Missing data were imputed per the method described in the SAP. The least square mean is computed from the result of the 20 analyses with imputed missing values
Time frame: 43 days
The Proportion of Participants With Their Demodex Mites Eradicated.
The proportion of participants with Demodex mites eradicated at Day 43 where eradication is defined as a mite density of 0 mites/lash for the analysis eye. The mite density is obtained by epilating four of more lashes and dividing the number of mites observed under the microscope by the number of lashes. The primary outcome analysis is the combined result from 20 analyses each with missing data imputed. Missing data were imputed per the method described in the SAP. The least square mean is computed from the result of the 20 analyses with imputed missing values
Time frame: 43 days
The Proportion of Participants Cured Based on a Composite of Collarette Score and Erythema Score
The proportion of participants cured where cure is defined as a composite of the collarettes, 0-2 lashes with collarettes on the upper eyelid of the analysis eye, and normal lid margin erythema for the upper eyelid of the analysis eye at Day 43. The primary outcome analysis is the combined result from 20 analyses each with missing data imputed. Missing data were imputed per the method described in the SAP. The least square mean is computed from the result of the 20 analyses with imputed missing values.
Time frame: 43 days
The Proportion of Participants Cured Based on Erythema Score.
The proportion of participants cured based on erythema where cure is defined as having a normal eyelid erythema of the analysis eye at day 43. The primary outcome analysis is the combined result from 20 analyses each with missing data imputed. Missing data were imputed per the method described in the SAP. The least square mean is computed from the result of the 20 analyses with imputed missing values.
Time frame: 43 days
| Milestone | Active | Control |
|---|---|---|
| Started | 203 | 209 |
| Completed | 193 | 200 |
| Not completed | 10 | 9 |
The proportion of subjects cured where cure is defined as 0-2 lashes with collarettes on the upper eyelid of the analysis eye. The primary outcome analysis is the combined result from 20 analyses each with missing data imputed. Missing data were imputed per the method described in the SAP. The least square mean is computed from the result of the 20 analyses with imputed missing values
| Proportion cured | Active | Control |
|---|---|---|
| The Proportion of Participants Cured Based on Their Collarette Score of 0 for the Upper Eyelid. | 0.547 ± 0.035 | 0.122 ± 0.023 |
The proportion of participants with Demodex mites eradicated at Day 43 where eradication is defined as a mite density of 0 mites/lash for the analysis eye. The mite density is obtained by epilating four of more lashes and dividing the number of mites observed under the microscope by the number of lashes. The primary outcome analysis is the combined result from 20 analyses each with missing data imputed. Missing data were imputed per the method described in the SAP. The least square mean is computed from the result of the 20 analyses with imputed missing values
| Proportion eradicated | Active | Control |
|---|---|---|
| The Proportion of Participants With Their Demodex Mites Eradicated. | 0.499 ± 0.036 | 0.14 ± 0.024 |
The proportion of participants cured where cure is defined as a composite of the collarettes, 0-2 lashes with collarettes on the upper eyelid of the analysis eye, and normal lid margin erythema for the upper eyelid of the analysis eye at Day 43. The primary outcome analysis is the combined result from 20 analyses each with missing data imputed. Missing data were imputed per the method described in the SAP. The least square mean is computed from the result of the 20 analyses with imputed missing values.
| Proportion cured | Active | Control |
|---|---|---|
| The Proportion of Participants Cured Based on a Composite of Collarette Score and Erythema Score | 0.187 ± 0.028 | 0.039 ± 0.014 |
The proportion of participants cured based on erythema where cure is defined as having a normal eyelid erythema of the analysis eye at day 43. The primary outcome analysis is the combined result from 20 analyses each with missing data imputed. Missing data were imputed per the method described in the SAP. The least square mean is computed from the result of the 20 analyses with imputed missing values.
| Proportion cured | Active | Control |
|---|---|---|
| The Proportion of Participants Cured Based on Erythema Score. | 0.303 ± 0.033 | 0.091 ± 0.02 |
Collected over 90 Days. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Active | 0/203 (0%) | 4/203 (2%) | 49/203 (24.1%) |
| Control | 0/209 (0%) | 3/209 (1.4%) | 28/209 (13.4%) |
| Event | Active | Control |
|---|---|---|
| Diabetic retinopathyEye disorders | 1/203 | 0/209 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/203 | 0/209 |
| Uterine prolapseReproductive system and breast disorders | 1/203 | 0/209 |
| Intestinal obstructionGastrointestinal disorders | 1/203 | 0/209 |
| Bladder CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/203 | 1/209 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/203 | 1/209 |
| Covid-19Infections and infestations | 0/203 | 1/209 |
| Event | Active | Control |
|---|---|---|
| Instillation site painGeneral disorders | 16/203 | 13/209 |
| Visual acuity reducedEye disorders | 5/203 | 6/209 |
| Dry eyeEye disorders | 4/203 | 2/209 |
| Punctate keratitisEye disorders | 4/203 | 1/209 |
| HordeolumInfections and infestations | 4/203 | 1/209 |
| ChalazionEye disorders | 3/203 | 0/209 |
| Conjunctival hyperaemiaEye disorders | 3/203 | 0/209 |
| Eyelid oedemaEye disorders | 3/203 | 1/209 |
| Urinary tract infectionInfections and infestations | 3/203 | 2/209 |
| NasopharyngitisInfections and infestations | 3/203 | 1/209 |
| Age, Continuous(years) | Active | Control | Total |
|---|---|---|---|
| Mean | 63.9 ± 15.15 | 65.1 ± 13.35 | 64.5 ± 14.26 |
| Age, Customized(Participants) | Active | Control | Total |
|---|---|---|---|
| < 65 years | 84 | 80 | 164 |
| ≥ 65 years | 119 | 129 | 248 |
| Sex: Female, Male(Participants) | Active | Control | Total |
|---|---|---|---|
| Female | 97 | 103 | 200 |
| Male | 106 | 106 | 212 |
| Ethnicity (NIH/OMB)(Participants) | Active | Control | Total |
|---|---|---|---|
| Hispanic or Latino | 17 | 17 | 34 |
| Not Hispanic or Latino | 186 | 192 | 378 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Active | Control | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 2 |
| Asian | 3 | 3 | 6 |
| Native Hawaiian or Other Pacific Islander | 2 | 0 | 2 |
| Black or African American | 20 | 15 | 35 |
| White | 176 | 187 | 363 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 3 | 3 |
| Region of Enrollment(Participants) | Active | Control | Total |
|---|---|---|---|
| United States | 203 | 209 | 412 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TP-03
Tarsus Pharmaceuticals, Inc.